Clinical Trials
New medicines would not be possible without patient participation in clinical trials; we are grateful to all those who make progress possible.
New medicines would not be possible without patient participation in clinical trials; we are grateful to all those who make progress possible.
At KalVista, we are focused on developing new oral treatments for HAE. Learn more about our clinical studies.
KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. Originally designed to enroll 24 pediatric patients, the trial was met with high demand and will ultimately enroll approximately 36 children aged 2 to 11 years across seven countries in North America, Europe and Asia. KONFIDENT-KID will collect safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric oral disintegrating tablet (ODT) formulation of sebetralstat.
The KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
The KONFIDENT Study (KVD900-301) was a Phase 3 clinical trial of sebetralstat for the oral, on-demand treatment of hereditary angioedema (HAE) attacks. The KONFIDENT Study is completed, and positive topline Phase 3 data results were reported in February 2024.
YOU ARE NOW LEAVING KALVISTA.COM
You are now being directed to another KalVista website that contains information about specific treatment(s)